• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by CVRx Inc.

    11/7/24 9:10:51 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care
    Get the next $CVRX alert in real time by email
    SC 13D/A 1 nea10-cvrx_18897.htm NEW ENTERPRISE ASSOCIATES 10 LP -- CVRX, INC. 13D/A(#1) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    CVRx, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    126638105

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600

    Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    November 5, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 126638105

    13D Page 2 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 8A, Limited Partnership

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 126638105

    13D Page 3 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 10, Limited Partnership

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

     CUSIP No. 126638105

    13D Page 4 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 10, Limited Partnership

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     CUSIP No. 126638105

    13D Page 5 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates VIII, Limited Partnership

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     CUSIP No. 126638105

    13D Page 6 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners VIII, Limited Partnership

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

    CUSIP No. 126638105

    13D Page 7 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 126638105

    13D Page 8 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 126638105

    13D Page 9 of 19 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    2,246,127 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    2,246,127 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,246,127 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    9.3%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 126638105

    13D Page 10 of 19 Pages    

     

    Item 1. Security and Issuer.

    This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D originally filed on July 15, 2021, and relates to the common stock, $0.01 par value (“Common Stock”), of CVRx, Inc. (the “Issuer”), having its principal executive office at 9201 West Broadway Avenue, Suite 650, Minneapolis, MN 55445.

     

    Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

     

     

     

    Item 2. Identity and Background.

    This statement is being filed by:

     

    (a)New Enterprise Associates 10, Limited Partnership (“NEA 10”); New Enterprise Associates 8A, Limited Partnership (“NEA 8A”); and New Enterprise Associates VIII, Limited Partnership (“NEA VIII” and, together with NEA 10 and NEA 8A, the “Funds”); and

     

    (b)NEA Partners 10, Limited Partnership (“NEA Partners 10”), the sole general partner of NEA 8A and NEA 10; NEA Partners VIII, Limited Partnership (“NEA Partners VIII” and, together with NEA Partners 10, the “GPLPs”), the sole general partner of NEA VIII; and Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”) and Scott D. Sandell (“Sandell”).

     

    Sandell is the sole individual general partner of NEA Partners 10. Florence, Makhzoumi and Sandell are each a member of the Executive Committee of NEA Management Company, LLC (the “Executive Committee”).

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of the Funds, the GPLPs and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Makhzoumi is 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence is 104 5th Ave., 19th Floor, New York, NY 10011.

     

    The principal business of each Fund is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 10 is to act as the sole general partner of NEA 8A and NEA 10. The principal business of NEA Partners VIII is to act as the sole general partner of NEA VIII. The principal business of Florence, Makhzoumi and Sandell is to manage the GPLPs, the Funds and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Each of NEA 10, NEA 8A, NEA Partners 10, NEA VIII and NEA Partners VIII is a limited partnership organized under the laws of the State of Delaware. Florence, Makhzoumi and Sandell are each a United States citizen.

     

     

     

     

    CUSIP No. 126638105

    13D Page 11 of 19 Pages    

     

     

    Item 3. Source and Amount of Funds or Other Consideration.

    Not applicable.

     

     

     

    Item 4. Purpose of Transaction.

     

    On November 5, 2024, NEA 8A and NEA VIII completed open market sales as part of a series of public sales whereby (1) NEA 8A sold in the aggregate 28,848 shares of Common Stock and (2) NEA VIII sold in the aggregate 28,463 shares of Common Stock, at a weighted average price of $15.2038 per share, with prices that ranged from $14.97 to $15.48 per share. The Funds undertake to provide to the staff of the Securities and Exchange Commission (the “SEC”), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the previous sentence.

     

    On November 6, 2024, NEA 8A and NEA VIII completed additional open market sales as part of a series of public sales whereby (1) NEA 8A sold in the aggregate 20,875 shares of Common Stock and (2) NEA VIII sold in the aggregate 20,595 shares of Common Stock, at a weighted average price of $15.3678, with prices that ranged from $15.00 to $15.75 per share. The Funds undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the previous sentence.

     

    On November 7, 2024, NEA 8A and NEA VIII completed additional open market sales as part of a series of public sales whereby (1) NEA 8A sold in the aggregate 12,903 shares of Common Stock and (2) NEA VIII sold in the aggregate 12,731 shares of Common Stock, at a weighted average price of $15.4539, with prices that ranged from $15.06 to $15.76 per share. The Funds undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the previous sentence. As of November 7, 2024, NEA 8A held 110,762 shares of Common Stock (the “NEA 8A Shares”) and NEA VIII held 109,282 shares of Common Stock (the “NEA VIII Shares”).

     

    Depending on market conditions, their continuing evaluation of the business and prospects of the Issuer and other factors, NEA 8A, NEA 10, NEA VIII and other Reporting Persons may dispose of additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

     

    (a)The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

    (b)An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

    (c)A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

    (d)Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e)Any material change in the present capitalization or dividend policy of the Issuer;

     

    (f)Any other material change in the Issuer’s business or corporate structure;

     

    (g)Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

    (h)Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i)

    A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

     

    (j)Any action similar to any of those enumerated above.

     

     

     

     

    CUSIP No. 126638105

    13D Page 12 of 19 Pages    

     

     

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)NEA 8A is the record owner of the NEA 8A Shares. As the sole general partner of NEA 8A, NEA Partners 10 may be deemed to own beneficially the NEA 8A Shares. As the sole general partner of NEA Partners 10, Sandell may be deemed to own beneficially the NEA 8A Shares.

     

    NEA 10 is the record owner of the NEA 10 Shares. As the sole general partner of NEA 10, NEA Partners 10 may be deemed to own beneficially the NEA 10 Shares. As the sole general partner of NEA Partners 10, Sandell may be deemed to own beneficially the NEA 10 Shares.

     

    NEA VIII is the record owner of the NEA VIII Shares. As the sole general partner of NEA VIII, NEA Partners VIII may be deemed to own beneficially the NEA VIII Shares.

     

    As individual members of the Executive Committee, which committee has been delegated approval rights with respect to dispositions of the NEA 8A Shares, the NEA 10 Shares, and the NEA VIII Shares, each of Florence and Makhzoumi may also be deemed to beneficially own the NEA 8A Shares, the NEA 10 Shares, and the NEA VIII Shares and Sandell may also be deemed to beneficially own the NEA VIII Shares.

     

    By virtue of their relationship as affiliated entities, whose controlling entities have overlapping individual controlling persons, each of NEA 8A, NEA 10, NEA Partners 10, NEA VIII, NEA Partners VIII, Florence, Makhzoumi and Sandell may be deemed to share the power to direct the disposition and vote of the NEA 8A Shares, the NEA 10 Shares, and the NEA VIII Shares.

     

    Each Reporting Person disclaims beneficial ownership of the NEA 8A Shares, the NEA 10 Shares, and the NEA VIII Shares other than those shares which such person owns of record.

     

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on the 24,263,663 shares of Common Stock reported to be outstanding as of October 25, 2024 on the Issuer’s Form 10-Q, filed with the SEC on November 1, 2024.

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)Not applicable.

     

     

     

    CUSIP No. 126638105

    13D Page 13 of 19 Pages    

     

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Not applicable.

     

     

      

    Item 7. Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 126638105

    13D Page 14 of 19 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:       November 7, 2024

     

     

     

    NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP

     

    By:

    NEA PARTNERS 10, LIMITED PARTNERSHIP

    General Partner

       

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

    NEW ENTERPRISE ASSOCIATES 8A, LIMITED PARTNERSHIP

     

    By:


    NEA PARTNERS 10, LIMITED PARTNERSHIP

    General Partner

      

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

      

    NEA PARTNERS 10, LIMITED PARTNERSHIP

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     

     

    CUSIP No. 126638105

    13D Page 15 of 19 Pages    

     

     

     

     

    NEW ENTERPRISE ASSOCIATES VIII, LIMITED PARTNERSHIP

     

    By:

    NEA PARTNERS VIII, LIMITED PARTNERSHIP
    General Partner

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

    NEA PARTNERS VIII, LIMITED PARTNERSHIP

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

                     *                        

    Scott D. Sandell

     

     

     

    EXECUTIVE COMMITTEE

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

    *By:  /s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

    This Amendment No. 1 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     
     

     

    CUSIP No. 126638105

    13D Page 16 of 19 Pages    

     

    EXHIBIT 1

     

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of CVRx, Inc.

     

    EXECUTED this 7th day of November, 2024.

     

     

     

    NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP

     

    By:

    NEA PARTNERS 10, LIMITED PARTNERSHIP

    General Partner

       

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

    NEW ENTERPRISE ASSOCIATES 8A, LIMITED PARTNERSHIP

     

    By:


    NEA PARTNERS 10, LIMITED PARTNERSHIP

    General Partner

      

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

      

    NEA PARTNERS 10, LIMITED PARTNERSHIP

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     

     

    CUSIP No. 126638105

    13D Page 17 of 19 Pages    

     

     

     

     

    NEW ENTERPRISE ASSOCIATES VIII, LIMITED PARTNERSHIP

     

    By:

    NEA PARTNERS VIII, LIMITED PARTNERSHIP
    General Partner

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

    NEA PARTNERS VIII, LIMITED PARTNERSHIP

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

                     *                        

    Scott D. Sandell

     

     

     

    EXECUTIVE COMMITTEE

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

    *By:  /s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

    This Agreement relating to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

     

     

     

    CUSIP No. 126638105

    13D Page 18 of 19 Pages    

    EXHIBIT 2

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

     

     

     

    /s/ Peter J. Barris  
    Peter J. Barris  
       
    /s/ Forest Baskett  
    Forest Baskett  
       
    /s/ Ali Behbahani  
    Ali Behbahani  
       
    /s/ Ronald D. Bernal  
    Ronald D. Bernal  
       
    /s/ Ann Bordetsky  
    Ann Bordetsky  
       
    /s/ Carmen Chang  
    Carmen Chang  
       
    /s/ Philip Chopin  
    Philip Chopin  
       
    /s/ Anthony A. Florence, Jr.  
    Anthony A. Florence, Jr.  
       
    /s/ Jonathan Golden  
    Jonathan Golden  
       
    /s/ Scott Gottlieb  
    Scott Gottlieb  

     

     

     

     

     

     

     

     

    CUSIP No. 126638105

    13D Page 19 of 19 Pages    

     

     

     

     

    /s/ Mark Hawkins  
    Mark Hawkins  
       
    /s/ Jeffrey R. Immelt  
    Jeffrey R. Immelt  
       
    /s/ Aaron Jacobson  
    Aaron Jacobson  
       
    /s/ Patrick J. Kerins  
    Patrick J. Kerins  
       
    /s/ Hilarie Koplow-McAdams  
    Hilarie Koplow-McAdams  
       
    /s/ Vanessa Larco  
    Vanessa Larco  
       
    /s/ Julio C. Lopez  
    Julio C. Lopez  
       
    /s/ Tiffany Le  
    Tiffany Le  
       
    /s/ Mohamad H. Makhzoumi  
    Mohamad H. Makhzoumi  
       
    /s/ Edward T. Mathers  
    Edward T. Mathers  
       
    /s/ Gregory Papadopoulos  
    Gregory Papadopoulos  
       
    /s/ Kavita Patel  
    Kavita Patel  
       
    /s/ Scott D. Sandell  
    Scott D. Sandell  
       
    /s/ A. Brooke Seawell  
    A. Brooke Seawell  
     
    /s/ Peter Sonsini  

    Peter Sonsini

     
       
    /s/ Melissa Taunton  
    Melissa Taunton  
       
    /s/ Paul E. Walker  
    Paul E. Walker  
       
    /s/ Rick Yang  
    Rick Yang  

     

     

     

     

    Get the next $CVRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVRX

    DatePrice TargetRatingAnalyst
    5/9/2025$7.00Neutral → Underweight
    Analyst
    1/14/2025Mkt Perform → Outperform
    William Blair
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    5/1/2024Outperform → Mkt Perform
    William Blair
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by CVRx Inc.

      SC 13D/A - CVRx, Inc. (0001235912) (Subject)

      11/7/24 9:10:51 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CVRx Inc.

      SC 13G/A - CVRx, Inc. (0001235912) (Subject)

      11/1/24 11:05:15 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

      SC 13G/A - CVRx, Inc. (0001235912) (Subject)

      2/6/24 7:56:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/14/25 5:27:07 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/13/25 7:12:40 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • PRES & CEO Hykes Kevin bought $24,200 worth of shares (5,000 units at $4.84), increasing direct ownership by 4% to 133,000 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/12/25 7:07:45 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CVRx, Inc. downgraded by Analyst with a new price target

      Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

      5/9/25 8:41:10 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx, Inc. upgraded by William Blair

      William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

      1/14/25 7:51:14 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

      Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

      9/10/24 7:46:21 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CVRx Reports First Quarter 2025 Financial and Operating Results

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

      5/8/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

      MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time

      4/24/25 4:30:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Reports Preliminary First Quarter 2025 Financial Results

      MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev

      4/7/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/14/25 5:27:07 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/13/25 7:12:40 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • PRES & CEO Hykes Kevin bought $24,200 worth of shares (5,000 units at $4.84), increasing direct ownership by 4% to 133,000 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/12/25 7:07:45 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Financials

    Live finance-specific insights

    See more
    • CVRx Reports First Quarter 2025 Financial and Operating Results

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

      5/8/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

      MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time

      4/24/25 4:30:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Reports Preliminary First Quarter 2025 Financial Results

      MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev

      4/7/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Leadership Updates

    Live Leadership Updates

    See more
    • CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

      MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

      6/25/24 6:50:00 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

      Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

      1/31/24 8:00:00 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors

      MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b

      12/20/22 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by CVRx Inc.

      10-Q - CVRx, Inc. (0001235912) (Filer)

      5/9/25 8:25:25 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CVRx, Inc. (0001235912) (Filer)

      5/8/25 4:09:03 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by CVRx Inc.

      DEF 14A - CVRx, Inc. (0001235912) (Filer)

      4/23/25 4:15:28 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care